Clover Health Investments, Corp.

Company Overview

Business Model: Clover Health's core value proposition is to empower physicians with technology to identify, manage, and treat chronic diseases earlier, leading to earlier diagnosis, treatment, and more affordable, accessible care. The Company primarily generates revenue through its Medicare Advantage ("MA") plans, including Preferred Provider Organization ("PPO") and Health Maintenance Organization ("HMO") offerings. Its proprietary software platform, Clover Assistant, supports clinical real-time decision-making by equipping clinicians with data and insights. In 2024, Clover Health launched Counterpart Health, Inc., a Software-as-a-Service ("SaaS") and Tech Enabled Services Solution, to license Clover Assistant technology (branded as Counterpart Assistant) to external payors and providers serving the Medicare eligible population, aiming for new growth and high-margin business opportunities.

Market Position: Clover Health aims to provide affordable, high-quality healthcare, particularly for Medicare eligible seniors in underserved markets, including those with at least two chronic diseases and those in socioeconomically deprived communities. The Company differentiates itself through its wide physician networks and the technology-enabled clinical decision-making facilitated by Clover Assistant. The MA market represented approximately $545 billion in annual spend in 2025 and is projected to grow to approximately $916 billion by 2030.

Recent Strategic Developments: In 2024, Clover Health launched Counterpart Health, Inc. to expand the reach of its Clover Assistant technology to external partners. The Company exited the ACO REACH Program in 2023. For the 2026 Annual Election Period, Clover Health announced a 53% year-over-year growth in its MA membership, entering 2026 with over 153,000 members, with over 97% enrolled in its PPO plans. The Centers for Medicare & Medicaid Services ("CMS") decreased the Star Rating of its PPO MA plans to 3.5 Stars for the 2026 rating year, while increasing its HMO MA plan rating to 4.0 Stars for the same period.

Geographic Footprint: Clover Health operates its MA plans in five states and 203 counties. The Company is remote-first and does not maintain a headquarters. It also has international operations, with a team of 41 employees in Hong Kong and other contracted operations in Canada and various other countries.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 18.5% (2025); 26.6% (2024)
• Operating Margin: -4.4% (2025); -3.3% (2024)
• Net Margin: -4.4% (2025); -3.1% (2024)

Investment in Growth:

• Capital Expenditures: $2,043k (2025); $1,556k (2024)
• Strategic Investments: Equity investment in Thyme Care, Inc. with a fair value of $3.9 million at December 31, 2025. Investment in Counterpart Health, Inc. for SaaS and Tech Enabled Services Solution.

Business Segment Analysis

Insurance Segment

Financial Performance:

• Revenue (Premiums earned, net): $1,891,732k (+40.7% YoY in 2025)
• Operating Margin (Segment gross profit): 14.5% (2025); 24.9% (2024)
• Key Growth Drivers: Primarily driven by a 33% increase in average members during 2025 and an increase in risk adjustment revenue resulting from the Company's high member retention rate. The use of Clover Assistant is designed to improve clinical decision-making and lower per member per month ("PMPM") medical claim expenses.

Product Portfolio:

• Offers Preferred Provider Organization ("PPO") and Health Maintenance Organization ("HMO") Medicare Advantage plans.
• Leverages Clover Assistant, a proprietary software platform, to empower providers with data-driven insights.
• Operates Clover Home Care, a longitudinal home-based primary care program for high-acuity members.

Market Dynamics:

• Focuses on Medicare eligible seniors in underserved markets, including those diagnosed with at least two chronic diseases and those living in communities within the top five deciles of socioeconomic deprivation.
• Aims to provide affordable, high-quality healthcare with wide physician networks and low average out-of-pocket costs for primary care provider ("PCP") and specialist co-pays.
• Offers open network plans where members pay the same cost-sharing for in-network and out-of-network PCP visits.

Counterpart Health

Financial Performance: Not yet significant to Clover Health's overall business or results of operations.

Product Portfolio:

• A Software-as-a-Service ("SaaS") and Tech Enabled Services Solution that brings the power of Clover Assistant technology to external payors and providers serving the Medicare eligible population under the brand name "Counterpart Assistant."

Market Dynamics:

• Aims to extend the benefits of data-driven proven technology and personalized care to a wider audience, enabling enhanced patient outcomes and reduced healthcare costs across the nation.
• Positioned as a complementary offering to drive growth and profitability with new SaaS and Tech-Enabled Services revenue streams and low startup costs.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $18,298k (5,069,423 shares) in 2025; $1,772k (1,838,309 shares) in 2024.
• Dividend Payments: Clover Health has never declared or paid cash dividends on its common stock and does not intend to do so in the foreseeable future, anticipating retention of future earnings for business development and corporate purposes.
• Future Capital Return Commitments: The Board authorized a share repurchase program of up to $20.0 million in Class A common stock over a two-year period on May 6, 2024, which was exhausted in the first quarter of 2025. The Company may enter into a new repurchase program in the future.

Balance Sheet Position:

• Cash and Equivalents (Consolidated): $78,301k at December 31, 2025.
• Total Debt: The parent company has notes payable, net of discount and deferred issuance costs, of $360k at December 31, 2025. A surplus note of $40,000k from Clover Insurance Company to the parent company, due December 31, 2020, remains unpaid with payment terms under review for extension until December 31, 2027, requiring prior written approval from the New Jersey Department of Banking and Insurance ("NJ DOBI").
• Net Cash Position: Not explicitly stated.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The $40.0 million surplus note's payment terms are under review for extension until December 31, 2027, and require regulatory approval for principal or interest payments.

Cash Flow Generation:

• Operating Cash Flow (from continuing operations): $(66,934)k (2025); $34,845k (2024).

Operational Excellence

Production & Service Model: Clover Health's operational philosophy is technology-first, centered on the Clover Assistant platform. This cloud-based software curates data from over 100 sources to provide physicians with data-driven insights and personalized care recommendations, aiming for earlier disease detection, identification, and management. The Company also operates Clover Home Care, a longitudinal home-based primary care program for its highest acuity members, powered by Clover Assistant.

Supply Chain Architecture: Key Suppliers & Partners:

• Plan Operations: UST HealthProof performs various plan operation functions, including claims, enrollment, contact center, medical management, payment integrity, revenue integrity, print, fulfillment, and certain IT functions.
• Oncology Care Management: Thyme Care, Inc. provides cancer care management services and develops a provider network for oncology care.
• Medical Records Retrieval: Credo (Medical Records Exchange, LLC) provides administrative services for medical records retrieval via electronic applications and a web portal platform.
• Value-Based Care Enablement: Guidehealth, LLC provides value-based care enablement and outsourced administrative services, focusing on medication adherence and patient outcomes.

Facility Network:

• Clover Health operates as a remote-first company.
• Research & Development: A significant portion of software research and development is performed internationally, including by a team of 41 employees in Hong Kong.

Operational Metrics:

• Insurance members at period end: 113,803 (December 31, 2025); 82,664 (December 31, 2024).
• Insurance Benefits expense ratio ("BER"): 90.9% (2025); 81.2% (2024).
• Normalized Insurance Benefits expense ratio: 91.5% (2025); 84.2% (2024).

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Utilizes direct mail, marketing materials on its website and the Internet, and telesales.
• Channel Partners: Leverages an extensive network of insurance brokers and field marketing organizations.
• Digital Platforms: Markets plans through its website and free marketing channels provided by the U.S. government, such as the Medicare Plan Finder.
• Co-branding: Enters into co-branding arrangements with providers and other provider institutions.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Not explicitly named, but the Company focuses on contracting with a wide array of primary care decision-makers.
• Strategic Partnerships: Collaborates with partners like UST HealthProof, Thyme Care, Inc., Credo, and Guidehealth, LLC.
• Customer Concentration: Approximately 87% of members were residents of New Jersey at December 31, 2025, with most concentrated in two metropolitan areas.

Geographic Revenue Distribution:

• New Jersey: Approximately 87% of total members at December 31, 2025.
• Growth Markets: Operates MA plans in five states and 203 counties, with a strategy to expand into virtually any market, including traditionally underserved markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The physician enablement space and Medicare segments (Medicare Advantage and Original Medicare) are highly competitive, characterized by rapidly changing technologies, evolving regulatory requirements, new product offerings, and constantly evolving beneficiary and provider preferences. The Medicare Advantage market was approximately $545 billion in 2025 and is expected to grow to approximately $916 billion by 2030.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Large National Insurers: United Health, Aetna, Humana, Centene, and Elevance Health.
• Regional Health Plans: Blue Cross Blue Shield affiliates, Alignment Health, Devoted Health, Oscar Health.
• Other Entities: Hospital systems and provider-based organizations.

Emerging Competitive Threats:

• Providers of healthcare technology platforms, EHR providers, telehealth providers, healthcare data analytics providers, and Accountable Care Organizations (ACOs).

Competitive Response Strategy: Clover Health competes by leveraging its Clover Assistant platform to improve clinical decision-making, offering competitive pricing, providing access to broad and open provider networks, offering flexible plan benefits, building brand strength, and focusing on beneficiary and provider satisfaction and financial stability.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Exposure to general economic conditions, inflation, fluctuating interest rates, and geopolitical uncertainty. Estimates of market opportunity and growth forecasts may prove inaccurate.
• Technology Disruption: Dependence on maintaining and improving Clover Assistant and its expansion through Counterpart Assistant. Risks include lower-than-expected adoption, failure to integrate with EHR systems, and competition from alternative products. Issues in the development and use of artificial intelligence ("AI") may result in reputational harm or liability.
• Customer Concentration: Members remain concentrated in certain geographic areas and populations (e.g., 87% in New Jersey), exposing the Company to unfavorable changes in local benefit costs, reimbursement rates, competition, and economic conditions.
• Demand Volatility: Member enrollment is highly dependent on the Medicare annual enrollment period and open enrollment period.
• Profitability: History of net losses and uncertainty in achieving or maintaining future profitability. Failure to effectively estimate, price for, and manage medical expenses, including medical loss ratios ("MLRs"), could decline profitability.
• Capital Requirements: May require additional capital to support business growth, which might not be available on acceptable terms or at all.
• Competition: Operates in a highly competitive industry with larger companies that may have stronger brands and greater resources. Consolidation among competitors could intensify competition.
• Brand & Innovation: Failure to develop widespread brand recognition or to continuously innovate and provide useful services could harm the business.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Reliance on third-party providers for computing infrastructure (e.g., Amazon Web Services, Google Cloud), network connectivity, and operational functions (e.g., UST HealthProof, Thyme Care, Inc., Credo, Guidehealth, LLC). Disruptions or failures by these third parties could adversely affect operations.
• Technology Reliability: Real or perceived errors, failures, vulnerabilities, or bugs in Clover Assistant could harm the business, as could service outages, interruptions, or delays in platform deployment.
• Human Capital: Intense competition for qualified personnel, dependence on senior management and key employees, and challenges in attracting and retaining talent, particularly in US and international offices.
• Growth Management: Inability to effectively manage growth (e.g., unexpected increase in members, rapid geographic expansion, sudden hiring growth) could lead to unexpected expenses or weaknesses in infrastructure.
• M&A Activities: Potential future merger and acquisition activities could require significant management attention, disrupt business, and dilute stockholder value.
• Accounting Estimates: If estimates or judgments relating to critical accounting policies, such as incurred but not reported ("IBNR") claims, prove incorrect, results of operations could be adversely affected.

Financial & Regulatory Risks

• Government Funding: Significant portion of revenues derived from programs funded by the U.S. federal government, exposing the Company to changes in government policy, funding levels, and regulatory interpretations.
• Medicare Advantage Dependence: Substantial portion of total revenues from Medicare Advantage premiums, making the Company vulnerable to changes in Medicare policies, funding, and regulations (e.g., ACA, risk adjustment payment system, Part D costs).
• State Regulations: Subject to state licensure requirements, corporate practice of medicine, and fee-splitting laws, with violations potentially leading to penalties or business restructuring.
• Quality & Performance Measures: Failure to maintain satisfactory quality and performance measures (e.g., CMS Star Ratings) may negatively affect premium rates, limit member growth, or result in contract termination.
• Regulatory Compliance: Highly regulated healthcare industry (Anti-Kickback Statute, Stark Law, HIPAA, FCA, OBBBA, IRA). Non-compliance can result in civil/criminal penalties, fines, and exclusion from government programs.
• FDA Regulation: Clover Assistant could become subject to FDA regulation as a medical device, requiring extensive approval processes and compliance.
• Statutory Capital: Required to maintain specific minimum statutory capital levels for regulated insurance subsidiaries, with potential for increased requirements.
• Privacy & Security: Use and disclosure of personally identifiable information ("PII") and protected health information ("PHI") is subject to federal and state privacy and security regulations (HIPAA, CCPA). Failure to comply or adequately secure information could result in significant liability or reputational harm.
• Legal Proceedings: Subject to investigations and litigation (e.g., past SEC inquiry, potential FCA lawsuits), which can be costly and time-consuming.

Geopolitical & External Risks

• International Operations: Direct operations in Hong Kong and Canada, and contracted operations elsewhere, expose the Company to political instability, disruptions in international trade, export control laws, and increased data security/privacy risks.
• Inflation Risk: Ongoing inflationary pressures and changes in interest rates could adversely affect operating results if increases in medical costs, prescription drug prices, provider reimbursement rates, or operating expenses are not fully offset by corresponding increases in Medicare Advantage benchmark rates.

Innovation & Technology Leadership

Research & Development Focus: Clover Health prioritizes continuous innovation in the Clover Assistant platform, investing in expanding its features and functionality. The Company's research and development team is responsible for the design, development, testing, and delivery of solutions for the platform, leveraging a closed feedback loop from provider interactions to guide future innovation. The Company is also expanding its AI capabilities in products, services, and tools, including generative AI.

Core Technology Areas:

• Clover Assistant: A purpose-built, cloud-based technology platform that synthesizes comprehensive, longitudinal data from over 100 sources. It uses machine learning, artificial intelligence, and rules-based insights to generate data-driven, personalized, and actionable recommendations for physicians at the point of care.
• EHR Integration: Significant investments have been made to embed Clover Assistant functionality seamlessly into major Electronic Health Record ("EHR") systems, including Epic, Cerner, and Athena.

Intellectual Property Portfolio: Clover Health relies on a combination of patent, copyright, trade secret, and trademark protection to safeguard its internally-developed technology and proprietary information. It holds a portfolio of patents and has pending patent applications, and has registered its trademarks in the United States and internationally.

Technology Partnerships: The Company integrates Clover Assistant with major EHR systems like Epic, Cerner, and Athena to enhance physician workflows.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's senior management and key employees are "at-will" employees. The Company does not have "key person" insurance on any employees.

Board Composition: The Board of Directors oversees the Company’s enterprise risk management program, with primary oversight of cybersecurity risk management delegated to its Audit Committee. Thomas Tran, a member of the Board and Chair of the Audit Committee, also serves as a director of Guidehealth, LLC.

Human Capital Strategy

Workforce Composition: At December 31, 2025, Clover Health had 724 employees. Approximately 93% of its workforce is in the U.S., 6% in Hong Kong, and less than 1% dispersed in various other countries.

Talent Management:

• Acquisition & Retention: The Company strives to attract and retain highly qualified talent by offering a collaborative and supportive work environment, competitive market compensation and benefits programs, and growth opportunities.
• Hiring Strategy: Operates a distributed team model to attract talent without geographic constraints.
• Employee Value Proposition: Total rewards program includes base salary, annual cash incentive opportunities, equity incentive awards, and comprehensive benefits (health insurance, paid time off, paid sick leave, paid parental leave, paid company-wide holidays, year-end "Week of Rest," U.S. 401(k) plan with Company match, and an employee stock purchase plan).

Diversity & Development:

• Development Programs: Provides customized 30/60/90-day onboarding plans and automated review cycles via its performance management system. The annual performance management cycle includes a 360 calibration review for employees at all levels.
• Culture & Engagement: Fosters a culture of transparency, engagement, and continuous feedback.

Environmental & Social Impact

Social Impact Initiatives: Clover Health is heavily invested in helping provide care for Medicare eligible seniors in underserved markets, including MA members diagnosed with at least two chronic diseases and those living in communities that fall within the top five deciles of socioeconomic deprivation. The Company's software-powered, primary care-centric approach aims to improve the quality of care and make it more affordable and accessible, regardless of a patient's socioeconomic status or geography.

Business Cyclicality & Seasonality

Demand Patterns: The maintenance and growth of Clover Health's member levels are highly dependent upon its success in attracting new members during the Medicare annual enrollment period and open enrollment period. Economic Sensitivity: The Company's business is affected by conditions and trends in the financial markets and general economic and political conditions, including inflation and fluctuating interest rates. Industry Cycles: The U.S. healthcare market is in the early stages of structural change and is rapidly evolving toward a more value-based care model.

Planning & Forecasting: Medicare Advantage plan bids are submitted to CMS in June of the year prior to the contract year, based on estimates of future medical costs over the fixed contract period.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• CMS Oversight: Comprehensive oversight from CMS, regulating MA plans, payments, information submission for risk adjustment, benefit design, eligibility, enrollment, marketing, record-keeping, quality assurance, claims payment, network adequacy, and provider relationships. Subject to CMS audits, including Risk Adjustments Data Validation audits.
• Privacy, Security, and Data Standards: Subject to numerous federal and state laws, including HIPAA (Privacy Rule, Security Rule, HITECH, breach notification) and state laws like the California Consumer Privacy Act ("CCPA") and Washington’s My Health My Data Law. These govern the collection, dissemination, use, privacy, confidentiality, security, availability, and integrity of personally identifiable information ("PII") and protected health information ("PHI").
• Fraud and Abuse Laws: Subject to federal laws like the Anti-Kickback Statute and the False Claims Act ("FCA"), and similar state laws, which prohibit activities such as kickbacks, fraudulent coding, billing for unnecessary services, and improper marketing.
• State Insurance Regulation: Regulated by state insurance departments (e.g., New Jersey Department of Banking and Insurance), requiring licenses, minimum capital levels, and adherence to sales, documentation, and administration practices.
• Corporate Practice of Medicine & Fee-Splitting: Subject to state laws prohibiting business corporations from practicing medicine or employing physicians to practice medicine, and from engaging in fee-splitting practices.
• ACA Provisions: Required to spend at least 85% of Medicare Advantage premiums on healthcare services, covered benefits, and quality improvement efforts (Medical Loss Ratio).
• Other Legislation: Subject to the Inflation Reduction Act of 2022 ("IRA") and the One Big Beautiful Bill Act ("OBBBA"), though the IRA's corporate alternative minimum tax did not apply in 2025, and OBBBA had no material impact on consolidated financial statements.

Trade & Export Controls:

• International Compliance: Non-U.S. operations are subject to U.S. laws regulating conduct abroad, such as export control laws and the Foreign Corrupt Practices Act ("FCPA").

Legal Proceedings:

• SEC Investigation: An inquiry from the U.S. Department of Justice ("DOJ") and a subpoena from the SEC related to disclosures and business aspects, including provider arrangements and Clover Assistant, were concluded with the SEC Staff not intending to recommend an enforcement action against the Company.
• Litigation Risk: Subject to various lawsuits in the ordinary course of business, including potential qui tam actions under the FCA.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's effective tax rate was zero for the years ended December 31, 2025, 2024, and 2023, primarily due to a full valuation allowance recorded against its U.S. deferred tax assets.
• Net Operating Loss Carryforwards (NOLs): At December 31, 2025, Clover Health had approximately $1,577.7 million in federal NOL carryforwards. Of this, $249.2 million begin to expire in 2035, and $1,328.5 million may be carried forward indefinitely (with exceptions for insurance companies).
• Section 382 Limitations: Prior ownership changes may limit the Company's ability to utilize pre-change NOLs.
• Tax Reform Impact: The Company was not subject to the 15% corporate alternative minimum tax under the Inflation Reduction Act of 2022 in 2025. The One Big Beautiful Bill Act, signed July 4, 2025, did not have a material impact on the Company’s consolidated financial statements.

Insurance & Risk Transfer

Risk Management Framework: Clover Health utilizes reinsurance agreements to manage its exposure to potential losses.

• Reinsurance Coverage: Renews a specific excess loss reinsurance agreement annually for its MA plan liabilities, reinsuring per covered person amounts in excess of $0.5 million for 2025.
• Life & Annuity Reinsurance: Acquired life policies and annuity contracts are 100% coinsured with third-party reinsurers (Southern Financial Life Insurance Company and Sagicor Life Insurance Company), transferring underwriting risk and administrative responsibilities.

Insurance Coverage: The Company maintains insurance covering medical malpractice claims and certain business interruptions, though coverage may not be sufficient for all potential losses.